The most common adverse events of any severity, reported with use of the drug Reyataz and one or more nucleoside, nucleotide and non-nucleoside reverse transcriptase inhibitors with a frequency of more than 10% and possibly related “to therapy were: nausea (20%), jaundice (13%) and diarrhea (10%).
jaundice was observed after a few days or months after initiation of treatment and less than 1% of patients led to drug discontinuation. Lipodystrophy buy proviron moderate or severe, have been reported with taking the drug Reyataz and one or more nucleoside, nucleotide and non-nucleoside reverse transcriptase inhibitors, and possibly related to treatment occurred in 5% of patients.
From the senses: often – yellowness of the sclera. On the part of metabolism: rarely – anorexia, increased appetite, weight loss, weight gain, post-marketing data (frequency uninstalled) – hyperglycemia, diabetes mellitus. Since hand reproduktienoy system: infrequent – gynecomastia: cardio-vascular system: . rare – increase in blood pressure, fainting, rarely – swelling, palpitations Post-marketing data (frequency not installed) – AV block of the second and third degree, lengthening of the QTc interval, cardiac arrhythmias such as «torsades des pointes».
From the respiratory system: rarely – shortness of breath. On the part of the liver and biliary tract: often – cholelithiasis; rarely – hepatitis; rarely – hepatosplenomegaly, postmarketing data (frequency unknown) – cholelithiasis, cholecystitis, cholestasis. General disorders:often – general weakness, fatigue; infrequently -. chest pain, fever, malaise The most common laboratory abnormalities in patients receiving treatment, which consisted of Reyataz and one or more nucleoside, nucleotide and nenukleozndnyh reverse transcriptase inhibitors, has buy proviron been an increase of total bilirubin (87%), especially indirect (unbound) bilirubin in blood serum. Other relevant abnormal laboratory parameters were noted in> 2% of patients: increasing the activity of creatine phosphokinase (7%), increased activity of alanine aminotransferase / serum glutamatshfuvattransaminazy (5%) reduction in the number of neutrophils (5%), the activity of aspartate aminotransferase / serum glutamatoksaloatsetattransaminazy (3% ), an increase of lipase activity (3%).
In clinical trials receive healthy volunteers medication doses up to 1200 mg dose was not accompanied by any adverse events.
The only case of an overdose buy proviron of the drug to HIV-infected patients who received 29.2 g of the drug (dose, 73 times the recommended dose of 400 mg) was accompanied by asymptomatic blockade both bundle of His feet and lengthening of the PR interval. These features disappeared spontaneously. The expected symptoms of overdose are jaundice unchanged results of liver function tests (due to increased concentration of indirect bilirubin), and heart rhythm disturbances (prolongation of the interval PR).
No specific antidote.
In case of overdose drug should monitor vital signs, to observe the general state patient monitor to designate gastric lavage, vomit to remove residual drug, administration of activated charcoal.
Dialysis ineffective for excretion of the drug, as atazanavir characterized in intensive liver metabolism and a high degree of protein binding.